In:
Molecular and Cellular Biomedical Sciences, Molecular and Cellular Biomedical Sciences (MCBS) Office, Vol. 2, No. 2 ( 2018-09-01), p. 48-
Abstract:
Stroke is a leading cause of death and long-term disability. This due to the ischemic event that cause by embolism of blockage blood flow. Thrombolytic agent plasminogen activator (tPA) is the only treatment approved by FDA. However, the used of tPA is limited to the short time window period. Neural stem cells (NSCs) show the potential to repair neuronal damage naturally after stroke. However, isolating NSCs is a challenging process due to the limitations of the method and its invasiveness. Some studies that had used mesenchymal stem cell (MSCs) as the main source of stem cell for therapy show that MSCs have the potency to differentiate into NSCs. in vitro, a differentiation process from MSC to NSC has been developed by combining the supplement or growth factor needed in the culture media.Keywords: stem cells, neuron stem cell, mesenchymal stem cell, stroke, trans-differentiation
Type of Medium:
Online Resource
ISSN:
2527-3442
,
2527-4384
DOI:
10.21705/mcbs.v2i2.28
Language:
Unknown
Publisher:
Molecular and Cellular Biomedical Sciences (MCBS) Office
Publication Date:
2018
detail.hit.zdb_id:
2940172-0
